

Boston makes a Korea change



[Elizabeth Cairns](#)

In a reminder that stents aren't just for the vasculature, Boston Scientific has bought MI Tech, a maker of devices designed not for blood vessels but to prop open other passages such as the oesophagus and bile ducts. Boston has acquired 64% of the South Korean group from its current owner, Synergy Innovation, for KRW291.2bn (\$230m). Though this is a smallish bolt-on by Boston's historical standards, so quiet has 2022 been for M&A that, astonishingly, it qualifies as the seventh-largest acquisition of the year so far. Otherwise Boston has followed its usual MO of buying a group with which it has an existing relationship: the US company has distributed MI Tech's Hanarostent franchise in Japan since 2015. Boston's shares rose 4% on the news.

Top 10 M&A deals of 2022

Announcement date	Acquirer	Target	Value (\$m)	Focus
Jan 1	Owens & Minor	Apria	1,450	Anaesthesia & respiratory
Apr 18	Archimed	Natus Medical	1,200	Anaesthesia & respiratory, neurology
Feb 7	The Cooper Companies	Reproductive Health business of Cook Group	875	Obstetrics & gynaecology
Jan 10	Medtronic	Affera	675	Cardiology
Apr 1	Biomérieux	Specific Diagnostics	426	In vitro diagnostics
Jan 5	Vera Whole Health	Castlight Health	370	Healthcare IT
Mar 31	Fresenius	Ivenix	240	Drug delivery
Jun 15	Boston Scientific	MI Tech	230	Gastroenterology
Jan 9	Exact Sciences	Prevention Genetics	190	In vitro diagnostics
Apr 18	Fulgent Genetics	Inform Diagnostics	170	In vitro diagnostics

Source: Evaluate Medtech & company communications.

[More from Evaluate Vantage](#)

Evaluate HQ
[44-\(0\)20-7377-0800](tel:44-020-7377-0800)

Evaluate Americas
[+1-617-573-9450](tel:+1-617-573-9450)

Evaluate APAC
[+81-\(0\)80-1164-4754](tel:+81-080-1164-4754)

© Copyright 2022 Evaluate Ltd.